Effectiveness and cost-effectiveness of a lifestyle modification programme in the prevention and treatment of subclinical, mild and moderate depression in primary care: a randomised clinical trial protocol

Alejandra Aguilar-Latorre, Capilla Navarro, Bárbara Oliván-Blázquez, Elena Gervilla, Rosa Magallón Botaya, Catalina Calafat-Villalonga, Mauro García-Toro, Santiago Boira, María Jesús Serrano-Ripoll, Alejandra Aguilar-Latorre, Capilla Navarro, Bárbara Oliván-Blázquez, Elena Gervilla, Rosa Magallón Botaya, Catalina Calafat-Villalonga, Mauro García-Toro, Santiago Boira, María Jesús Serrano-Ripoll

Abstract

Introduction: Major depression is a highly prevalent pathology that is currently the second most common cause of disease-induced disability in our society. The onset and continuation of depression may be related to a wide variety of biological and psychosocial factors, many of which are linked to different lifestyle aspects. Therefore, health systems must design and implement health promotion and lifestyle modification programmes (LMPs), taking into account personal factors and facilitators. The main objective of this protocol is to analyse the clinical effectiveness, cost-effectiveness and cost utility of an LMP and an LMP with information and communication technologies (ICTs) as adjunctive treatment for depression in primary care patients. The secondary objectives are to analyse the clinical effectiveness in the subgroup that presents comorbidity and to analyse the correlation between personal factors on health behaviour and lifestyle patterns.

Methods and analysis: A randomised, multicenter pragmatic clinical trial with three parallel groups consisting of primary healthcare patients suffering from subclinical, mild or moderate depression. The following interventions will be used: (1) Usual antidepressant treatment with psychological advice and/or psychotropic drugs prescribed by the general practitioner (treatment as usual (TAU)). (2) TAU+LMP. A programme to be imparted in six weekly 90-minute group sessions, intended to improve the following aspects: behavioural activation+daily physical activity+adherence to the Mediterranean diet pattern+sleep hygiene+careful exposure to sunlight. (3) TAU+LMP+ICTs: healthy lifestyle recommendations (TAU+LMP)+monitoring using ICTs (a wearable smartwatch). The primary outcome will be the depressive symptomatology and the secondary outcomes will be the quality of life, the use of health and social resources, personal factors on health behaviour, social support, lifestyle patterns and chronic comorbid pathology. Data will be collected before and after the intervention, with 6-month and 12-month follow-ups.

Ethics and dissemination: This study has been approved by the Clinical Research Ethics Committee of Aragón (approval number: C.P.-C.I. PI18/286) and the Research Ethics Committee of the Balearic Islands (IB3950/19 PI). Data distribution will be anonymous. Results will be disseminated via conferences and papers published in peer-reviewed, open-access journals.

Trial registration number: ClinicalTrials.gov Registry (NCT03951350).

Keywords: clinical trials; depression & mood disorders; primary care.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flowchart of the study: randomisation, sampling and monitoring of patients. GP, general practitioner; ICTs, information and communication technologies; ITT, intention to treat; LMP, lifestyle modification programme; MI, multiple imputation; TAU, treatment as usual.

References

    1. Ferrari AJ, Charlson FJ, Norman RE, et al. . Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013.
    1. Gabilondo A, Rojas-Farreras S, Vilagut G, et al. . Epidemiology of major depressive episode in a southern European country: results from the ESEMeD-Spain project. J Affect Disord 2010;120:76–85. 10.1016/j.jad.2009.04.016
    1. Department of Information Evidence and Research WHO . WHO methods and data sources for global burden of disease estimates 2000-2015 [online]. Global Health Estimates Technical Paper WHO/HIS/IER/GHE/2017.1, 2017. Available:
    1. Alonso J, Angermeyer MC, Bernert S, et al. . Prevalence of mental disorders in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatrica Scandinavica, supplement, 2004.
    1. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health 2013;34:119–38. 10.1146/annurev-publhealth-031912-114409
    1. Vindel AC, Salguero JM, Wood CM, et al. . La depresión en atención primaria: prevalencia, diagnóstico Y tratamiento. Papeles del psicólogo 2012;33:2–11.
    1. Codony M, Alonso J, Almansa J, et al. . Mental health care use in the Spanish general populations. Results of the ESEMeD-Spain study | Utilización de Los servicios de salud mental en La población General española. Resultados del estudio ESEMeD-España. Actas españolas Psiquiatr 2007;35:21–8.
    1. Andlin-Sobocki P, Jönsson B, Wittchen HU, et al. . Cost of disorders of the brain in Europe. Eur J Neurol 2005.
    1. Alonso J, Angermeyer MC, Bernert S, et al. . Use of mental health services in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004:47–54. 10.1111/j.1600-0047.2004.00330.x
    1. In:Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res 2002;53:849–57. 10.1016/s0022-3999(02)00304-5
    1. O’Neil A, Jacka FN, Quirk SE, et al. . A shared framework for the common mental disorders and non-communicable disease: key considerations for disease prevention and control. BMC Psychiatry 2015;15.
    1. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003;54:216–26. 10.1016/S0006-3223(03)00273-7
    1. Aragonès E, Piñol JL, Labad A, et al. . Prevalence and determinants of depressive disorders in primary care practice in Spain. Int J Psychiatry Med 2004;34:21–35. 10.2190/C25N-W4NY-BN8W-TXN2
    1. Davidson JRT. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010;71:e04. 10.4088/JCP.9058se1c.04gry
    1. Cuijpers P, van Straten A, van Schaik A, et al. . Psychological treatment of depression in primary care: a meta-analysis. British Journal of General Practice 2009;59:e51–60. 10.3399/bjgp09X395139
    1. National Collaborating Centre for Mental Health . Depression: the NICE guideline on the treatment and management of depression in adults. Economist 2010.
    1. Wittchen HU, Jacobi F, Rehm J, et al. . The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology 2011;21:655–79. 10.1016/j.euroneuro.2011.07.018
    1. Hidaka BH. Depression as a disease of modernity: explanations for increasing prevalence. J Affect Disord 2012;140:205–14. 10.1016/j.jad.2011.12.036
    1. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012;379:1045–55. 10.1016/S0140-6736(11)60602-8
    1. Lopresti AL, Hood SD, Drummond PD. A review of lifestyle factors that contribute to important pathways associated with major depression: diet, sleep and exercise. J Affect Disord 2013;148:12–27. 10.1016/j.jad.2013.01.014
    1. Toobert DJ, Glasgow RE, Strycker LA, et al. . Long-term effects of the Mediterranean lifestyle program: a randomized clinical trial for postmenopausal women with type 2 diabetes. Int J Behav Nutr Phys Act 2007;4:1. 10.1186/1479-5868-4-1
    1. García-Toro M, Ibarra O, Gili M, et al. . Four hygienic-dietary recommendations as add-on treatment in depression a randomized-controlled trial. J Affect Disord [Internet] 2012;140:200–3.
    1. Olivan-Blázquez B, Montero-Marin J, García-Toro M, et al. . Facilitators and barriers to modifying dietary and hygiene behaviours as adjuvant treatment in patients with depression in primary care: a qualitative study. BMC Psychiatry 2018;18:1–12. 10.1186/s12888-018-1779-7
    1. Forsyth A, Deane FP, Williams P. A lifestyle intervention for primary care patients with depression and anxiety: A randomised controlled trial. Psychiatry Res 2015:1–8.
    1. Harvey SB, Overland S, Hatch SL, et al. . Exercise and the prevention of depression: results of the HUNT cohort study. Am J Psychiatry 2018.
    1. Roca M, Kohls E, Gili M, et al. . Prevention of depression through nutritional strategies in high-risk persons: rationale and design of the MooDFOOD prevention trial. BMC Psychiatry 2016;16. 10.1186/s12888-016-0900-z
    1. Sánchez-Villegas A, Henríquez P, Bes-Rastrollo M, et al. . Mediterranean diet and depression. Public Health Nutr 2006;9:1104–9. 10.1017/S1368980007668578
    1. Meerlo P, Havekes R, Steiger A. Chronically restricted or disrupted sleep as a causal factor in the development of depression. Curr Top Behav Neurosci 2015.
    1. Coughlin JW, Smith MT. Sleep, obesity, and weight loss in adults: is there a rationale for providing sleep interventions in the treatment of obesity? Int Rev Psychiatry 2014.
    1. Tuunainen A, Kripke DF, Endo T, et al. . Light therapy for non-seasonal depression. Cochrane Database Syst Rev 2004;64:CD004050. 10.1002/14651858.CD004050.pub2
    1. Golden RN, Gaynes BN, Ekstrom RD, et al. . The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. American Journal of Psychiatry 2005;162:656–62. 10.1176/appi.ajp.162.4.656
    1. Antonovsky A. The salutogenic model as a theory to guide health promotion. Health Promot Int 1996;11:11–18. 10.1093/heapro/11.1.11
    1. NICE . Behaviour change: individual approaches [online], 2014. Available:
    1. Beck A, Steer R, Ball R, et al. . Comparison of beck depression 1 in psychiatric inventories -1A and - outpatients. J Pers Assess 1996;67:588–97.
    1. Ferrando L, Bobes J, MINI GJ. Mini international neuropsychiatric interview. Versión en Español 5.0.0 DSM-IV. Instrumentos Detección y Orientación Diagnóstica 2000.
    1. Button KS, Kounali D, Thomas L, et al. . Minimal clinically important difference on the Beck Depression Inventory-II according to the patient’s perspective. Psychol Med 2015.
    1. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978.
    1. Borek AJ, Abraham C, Greaves CJ, et al. . Identifying change processes in group-based health behaviour-change interventions: development of the mechanisms of action in group-based interventions (MAGI) framework. Health Psychol Rev 2019;13:227–47. 10.1080/17437199.2019.1625282
    1. Sanz J, García-Vera MP, Espinosa R, et al. . Spanish adaptation of the Beck depression Inventory-II (BDI-II): 3. psychometric features in patiens with psychological disorders. Clínica y Salud 2005;16:121–42
    1. Brooks R, De Charro F. EuroQol: the current state of play. health policy. New York, 1996.
    1. The EuroQol Group . EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208. 10.1016/0168-8510(90)90421-9
    1. Badia X, Roset M, Montserrat S, et al. . [The Spanish version of EuroQol: a description and its applications. European quality of life scale]. Med Clin 1999.
    1. Seoane B, de la Iglesia F, Nicolás R, et al. . Análisis factorial de la calidad de vida relacionada Con La salud de pacientes que ingresan en Una unidad de corta estancia médica. Rev. méd. Chile 2009;137.
    1. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005;14:1523–32. 10.1007/s11136-004-7713-0
    1. WHO . International classification of diseases (ICD-10). Fam Pract Manag 2010.
    1. Sherbourne CD, Stewart AL. The mos social support survey. Soc Sci Med 1991;32:705–14. 10.1016/0277-9536(91)90150-B
    1. de la Revilla-Ahumada L, Luna del Castillo J. Bailón Muñoz E MMI. [Validation of a questionnaire to measured social support in Primary Care]. Med Fam 2005.
    1. Knapp M. Economic evaluation of mental health care. In: Contemporary Psychiatry, 2001.
    1. Vazquez-Barquero JL, Gaite L, Cuesta MJ, et al. . Spanish version of the CSRI: A mental health cost evaluation interview. [Spanish version of the CSRI: A mental health cost evaluation interview]. Archivos de Neurobiología 1997.
    1. Kim Y, Park I, Kang M. Convergent validity of the International physical activity questionnaire (IPAQ): meta-analysis. Public Health Nutr 2013;16:440–52. 10.1017/S1368980012002996
    1. Roman-Viñas B, Serra-Majem L, Hagströmer M, et al. . International physical activity questionnaire: reliability and validity in a Spanish population. Eur J Sport Sci 2010;10:297–304. 10.1080/17461390903426667
    1. Kurtze N, Rangul V, Hustvedt B-E. Reliability and validity of the International physical activity questionnaire in the Nord-Trøndelag health study (Hunt) population of men. BMC Med Res Methodol 2008;8:1–9. 10.1186/1471-2288-8-63
    1. Martínez-González Miguel Ángel, Corella D, Salas-Salvadó J, et al. . Cohort profile: design and methods of the PREDIMED study. Int J Epidemiol 2012;41:377–85. 10.1093/ije/dyq250
    1. Schröder H, Fitó M, Estruch R, et al. . A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. J Nutr 2011;141:1140–5. 10.3945/jn.110.135566
    1. Buysse DJ, Reynolds CF, Monk TH, et al. . The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213. 10.1016/0165-1781(89)90047-4
    1. Royuela Rico A, Macías Fernández JA. Propiedades clinimétricas de la versión castellana del Cuestionario de Pittsburgh. Vigilia-Sueño, 1997.
    1. Sherer M, Maddux JE, Mercandante B, et al. . The self-efficacy scale: construction and validation. Psychol Rep 1982.
    1. Hibbard JH, Stockard J, Mahoney ER, et al. . Development of the patient activation measure (PAM): Conceptualizing and measuring activation in patients and consumers. Health Serv Res 2004;39:1005–26. 10.1111/j.1475-6773.2004.00269.x
    1. Antonovsky A. The structure and properties of the sense of coherence scale. Soc Sci Med 1993.
    1. Sørensen K, Pelikan JM, Röthlin F, et al. . Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU). Eur J Public Health 2015;25:1053–8. 10.1093/eurpub/ckv043
    1. Guilera G, Barrios M, Penelo E, et al. . Validation of the Spanish version of the irrational procrastination scale (iPS). PLoS One 2018;13:e0190806. 10.1371/journal.pone.0190806
    1. López-Torrecillas F, García J, Cañadas GA, et al. . Validity of self-efficacy scale scores for a Spanish sample. Psychol Rep 2006;98:437–50. 10.2466/pr0.98.2.437-450
    1. Moreno Chico C, González de Paz L, Monforte Royo C, et al. . Gallart fernández puebla A. Adaptación y validación de la escala de evaluación de la activación “Patient Activation Measure 13” (PAM13) en una muestra de pacientes crónicos visitados en CAP Rambla de MútuaTerrassa. XXIV Premi d’infermeria 2018;2018.
    1. Moreno B, Alonso M, Álvaréz E. Sentido de coherencia, personalidad resistente, autoestima Y salud. Rev Psicol la salud 1997;9:115–37.
    1. Nolasco A, Barona C, Tamayo-Fonseca N, et al. . Health literacy: psychometric behaviour of the HLS-EU-Q16 questionnaire. Gac Sanit [Internet] 2018:8–11.
    1. Arousal SP. Avoidant and decisional procrastinators: do they exist? Pers Individ Dif 2010.
    1. IBM Corp . Released. IBM SPSS statistics version 25.0, 2017.
    1. R Core Team . R: a language and environment for statistical computing, 2019.
    1. Schulz KF, Altman DC, Moher D. Consort 2010 statement: updated guidelines for reporting parallel group randomised trials. Ital J Public Health 2010.
    1. Van Hout BA, MJ A, Gordon GS, et al. . And C/E‐ratios alongside a clinical trial. Health Econ 1994;3:309–19.
    1. Romero-Sanchiz P, Nogueira-Arjona R, García-Ruiz A, et al. . Economic evaluation of a guided and unguided Internet-based CBT intervention for major depression: results from a multi-center, three-armed randomized controlled trial conducted in primary care. PLoS One 2017;12:e0172741. 10.1371/journal.pone.0172741
    1. Oblikue Consulting . Oblikue Database [online]. Available: [Accessed 29 Oct 2019].
    1. Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by Chained. J Stat Softw 2011.
    1. Smithson S, Pignone MP. Screening adults for depression in primary care. Med Clin North Am 2017;101:807–21. 10.1016/j.mcna.2017.03.010
    1. Craven MA, Bland R. Depression in primary care: current and future challenges. Can J Psychiatry 2013;58:442–8. 10.1177/070674371305800802
    1. Pence BW, O’Donnell JK, Gaynes BN. The depression treatment cascade in primary care: a public health perspective. Curr Psychiatry Rep 2012;14:328–35. 10.1007/s11920-012-0274-y
    1. Nieuwsma JA, Trivedi RB, McDuffie J, et al. . Brief psychotherapy for depression: a systematic review and meta-analysis. Int J Psychiatry Med 2012;43:129–51. 10.2190/PM.43.2.c
    1. Piper WE. Underutilization of short-term group therapy: enigmatic or understandable? Psychotherapy Research 2008;18:127–38. 10.1080/10503300701867512
    1. Simmonds-Buckley M, Kellett S, Waller G. Acceptability and efficacy of group behavioral activation for depression among adults: a meta-analysis. Behav Ther 2019;50:864–85. 10.1016/j.beth.2019.01.003
    1. Biggs K, Hind D, Gossage-Worrall R, et al. . Challenges in the design, planning and implementation of trials evaluating group interventions. Trials 2020;21:1–16. 10.1186/s13063-019-3807-4

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren